AstraZeneca/$AZN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About AstraZeneca
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
Ticker
$AZN
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
94,300
ISIN
US0463531089
Website
AstraZeneca Metrics
BasicAdvanced
$222B
14.44
$4.97
0.18
$1.52
2.87%
Price and volume
Market cap
$222B
Beta
0.18
52-week high
$87.01
52-week low
$61.24
Average daily volume
4.1M
Dividend rate
$1.52
Financial strength
Current ratio
0.897
Quick ratio
0.694
Long term debt to equity
67.922
Total debt to equity
77.112
Dividend payout ratio (TTM)
63.60%
Interest coverage (TTM)
10.16%
Profitability
EBITDA (TTM)
18,277
Gross margin (TTM)
82.44%
Net profit margin (TTM)
14.14%
Operating margin (TTM)
24.75%
Effective tax rate (TTM)
16.26%
Revenue per employee (TTM)
$580,000
Management effectiveness
Return on assets (TTM)
8.16%
Return on equity (TTM)
19.79%
Valuation
Price to earnings (TTM)
14.436
Price to revenue (TTM)
2.023
Price to book
4.03
Price to tangible book (TTM)
-9.37
Price to free cash flow (TTM)
12.095
Free cash flow yield (TTM)
8.27%
Free cash flow per share (TTM)
593.13%
Dividend yield (TTM)
2.12%
Forward dividend yield
2.87%
Growth
Revenue change (TTM)
15.48%
Earnings per share change (TTM)
22.71%
3-year revenue growth (CAGR)
9.84%
10-year revenue growth (CAGR)
7.72%
3-year earnings per share growth (CAGR)
90.42%
10-year earnings per share growth (CAGR)
17.24%
3-year dividend per share growth (CAGR)
2.60%
10-year dividend per share growth (CAGR)
1.02%
What the Analysts think about AstraZeneca
Analyst ratings (Buy, Hold, Sell) for AstraZeneca stock.
Bulls say / Bears say
AstraZeneca reported a 10% year-on-year increase in revenue to $13.6 billion in Q1 2025, driven by strong sales in cancer drugs and biopharmaceuticals. (ft.com)
The company is investing $2.5 billion in a new research center in Beijing, reflecting its commitment to the Chinese market despite recent challenges. (fastbull.com)
Analysts maintain a 'Buy' rating on AstraZeneca, with price targets up to $99, indicating confidence in the company's growth prospects. (markets.businessinsider.com)
AstraZeneca faces a US class action lawsuit alleging misleading statements about regulatory investigations in China, which could impact investor confidence. (ft.com)
The detention of AstraZeneca's top executive in China and ongoing regulatory probes pose significant operational risks in a key market. (reuters.com)
Potential US tariffs on pharmaceutical products from the EU could affect AstraZeneca's financial performance if implemented. (reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 28 Jun 2025.
AstraZeneca Financial Performance
Revenues and expenses
AstraZeneca Earnings Performance
Company profitability
AstraZeneca News
AllArticlesVideos
AstraZeneca shares open lower after rare disease drug fails to meet main trial goal
Proactive Investors·1 hour ago
AstraZeneca drug fails main goal of late-stage amyloidosis study
Reuters·2 hours ago
AstraZeneca shares show signs of life after successful trials of hypertension drug
Market Watch·2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for AstraZeneca stock?
AstraZeneca (AZN) has a market cap of $222B as of July 16, 2025.
What is the P/E ratio for AstraZeneca stock?
The price to earnings (P/E) ratio for AstraZeneca (AZN) stock is 14.44 as of July 16, 2025.
Does AstraZeneca stock pay dividends?
Yes, the AstraZeneca (AZN) stock pays dividends to shareholders. As of July 16, 2025, the dividend rate is $1.52 and the yield is 2.87%. AstraZeneca has a payout ratio of 63.6% on a trailing twelve-month basis.
When is the next AstraZeneca dividend payment date?
The next AstraZeneca (AZN) dividend payment date is unconfirmed.
What is the beta indicator for AstraZeneca?
AstraZeneca (AZN) has a beta rating of 0.18. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.